• Galapagos NV, of Mechelen, Belgium, said its Biofocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim GmbH, of Ingelheim, Germany, to apply its drug discovery services to an undisclosed target within Boehringer’s drug discovery portfolio. Financial terms were not disclosed.